IMUX - Immunic

-

$undefined

N/A

(N/A)

Immunic NasdaqGS:IMUX Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Location: 1200 Avenue of the Americas, New York, NY, 10036, United States | Website: https://imux.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

55.1M

Cash

35.67M

Avg Qtr Burn

-21.19M

Short % of Float

4.24%

Insider Ownership

0.99%

Institutional Own.

44.84%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Vidofludimus calcium (IMU-838) Details
Multiple sclerosis, Autoimmune disease

Phase 3

Data readout

Vidofludimus calcium (IMU-838) Details
Bowel disorder, Inflammatory bowel disease, Ulcerative colitis

Phase 2b

Update

Vidofludimus calcium (IMU-838) Details
COVID-19, Infectious disease

Phase 2

Update

Vidofludimus calcium (IMU-838) Details
Multiple sclerosis, Autoimmune disease

Phase 2

Update

IMU-856 Details
Celiac disease

Phase 2

Initiation

Failed

Discontinued

Vidofludimus calcium (IMU-838) Details
Primary sclerosing cholangitis, Bile duct disease, Liver disease

Failed

Discontinued